Alterations in metabolic pathways and networks in Alzheimer's disease

Translational Psychiatry

Volumn 3, Issue , 2013, Pages

  Kaddurah Daouk, R ^a,g   Zhu, H ^a   Sharma, S ^a,b   Bogdanov, M ^a,c   Rozen, S G ^d   Matson, W ^b   Oki, N O ^e   Motsinger Reif, A A ^e   Churchill, E ^a   Lei, Z ^d   Appleby, D ^f   Kling, M A ^f   Trojanowski, J Q ^f   Doraiswamy, P M ^a   Arnold, S E ^f  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

^e NORTH CAROLINA STATE UNIVERSITY   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Metabolomics; Partial network reconstruction; Pathway analysis

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; CHOLINESTERASE INHIBITOR; GLUTATHIONE; MEMANTINE; METHIONINE; NORADRENALIN; PURINE; TAU PROTEIN; TRYPTOPHAN; VANILMANDELIC ACID; XANTHOSINE; BIOLOGICAL MARKER;

ADULT; AGE; AGED; ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SEVERITY; DRUG USE; EDUCATIONAL STATUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLISM; METABOLITE; METABOLOMICS; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; ONSET AGE; PROTEIN METABOLISM; CASE CONTROL STUDY; LIQUID CHROMATOGRAPHY; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; METABOLOMICS; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES;

EID: 84878638145     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2013.18     Document Type: Article

References (33)

1. O'Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci 2011; 34: 185-204.
2. Di Paolo G, Kim TW. Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci 2011; 12: 284-296.
3. Patti GJ, Yanes O, Siuzdak G. Innovation: Metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol 2012; 13: 263-269.
4. Kaddurah-Daouk R, Krishnan KR. Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology 2009; 34: 173-186.
5. Sato Y, Suzuki I, Nakamura T, Bernier F, Aoshima K, Oda Y. Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology. J Lipid Res 2012; 53: 567-576.
6. Han X, Rozen S, Boyle SH, Hellegers C, Cheng H, Burke JR et al. Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One 2011; 6: e21643.
7. Kaddurah-Daouk R, Rozen S, Matson W, Han X, Hulette CM, Burke JR et al. Metabolomic changes in autopsy-confirmed Alzheimer's disease. Alzheimers Dement 2011; 7: 309-317.
8. Czech C, Berndt P, Busch K, Schmitz O, Wiemer J, Most V et al. Metabolite profiling of Alzheimer's disease cerebrospinal fluid. PLoS One 2012; 7: 16.
9. Oresic M, Hyotylainen T, Herukka SK, Sysi-Aho M, Mattila I, Julkunen V et al. Metabolome in progression to Alzheimer's disease. Transl Psychiatry 2011; 1: e57.
10. Kaddurah-Daouk R, Boyle S, Matson W, Sharma S, Matson S, Zhu H et al. Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Transl Psychiatry 2011; 1: e26.
11. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944. (Pubitemid 14076461)
12. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999; 56: 303-308. (Pubitemid 29120227)
13. Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease. Methods 2012; 56: 484-493.
14. Peng J, Wang P, Zhou N, Zhu J. Partial correlation estimation by joint sparse regression models. J Am Stat Assoc 2009; 104: 735-746.
15. Meinshausen N, Buhlmann P. High dimensional graphs and variable selection with the Lasso. Ann Statist 2006; 34: 1436-1462. (Pubitemid 44231168)
16. Vogel T, Dali-Youcef N, Kaltenbach G, Andres E. Homocysteine, vitamin B12, folate and cognitive functions: a systematic and critical review of the literature. Int J Clin Pract 2009; 63: 1061-1067.
17. Popp J, Lewczuk P, Linnebank M, Cvetanovska G, Smulders Y, Ko? lsch H et al. Homocysteine metabolism and cerebrospinal fluid markers for Alzheimer's disease. J Alzheimers Dis 2009; 18: 819-828.
18. Ballatori N, Krance SM, Notenboom S, Shi S, Tieu K, Hammond CL. Glutathione dysregulation and the etiology and progression of human diseases. Biol Chem 2009; 390: 191-214.
19. Boyd-Kimball D, Sultana R, Abdul HM, Butterfield DA. Gamma- glutamylcysteine ethyl ester-induced up-regulation of glutathione protects neurons against Abeta(1-42)-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. J Neurosci Res 2002; 79: 700-706. (Pubitemid 40476449)
20. Zampagni M, Wright D, Cascella R, D'Adamio G, Casamenti F, Evangelisti E et al. Novel S-acyl glutathione derivatives prevent amyloid oxidative stress and cholinergic dysfunction in Alzheimer disease models. Free Radic Biol Med 2012; 52: 1362-1371.
21. Bondareff W, Mountjoy CQ, Roth M. Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology 1982; 32: 164-168. (Pubitemid 12223999)
22. Shearman E, Rossi S, Szasz B, Juranyi Z, Fallon S, Pomara N et al. Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: a microdialysis study. Brain Res Bull 2006; 69: 204-213. (Pubitemid 43375876)
23. Gulyas B, Pavlova E, Kasa P, Gulya K, Bakota L, Vá rszegi S et al. Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography. Neurochem Int 2011; 58: 60-68.
24. Wang PN, Liu HC, Liu TY, Chu A, Hong CJ, Lin KN et al. Estrogen-metabolizing gene COMT polymorphism synergistic APOE epsilon4 allele increases the risk of Alzheimer disease. Dement Geriatr Cogn Disord 2005; 19: 120-125. (Pubitemid 40868038)
25. Martinez MF, Martin XE, Alcelay LG, Flores JC, Valiente JM, Juanbeltz BI et al. The COMT Val158 Met polymorphism as an associated risk factor for Alzheimer disease and mild cognitive impairment in APOE 4 carriers. BMC Neurosci 2009; 10: 125-130.
26. Borroni B, Grassi M, Costanzi C, Zanetti M, Archetti S, Franzoni S et al. Haplotypes in cathechol-O-methyltransferase gene confer increased risk for psychosis in Alzheimer disease. Neurobiol Aging 2007; 28: 1231-1238. (Pubitemid 46824011)
27. Kincses ZT, Toldi J, Vecsei L. Kynurenines, neurodegeneration and Alzheimer's disease. J Cell Mol Med 2010; 14: 2045-2054.
28. Albasanz JL, Perez S, Barrachina M, Ferrer I, Martin M. Up-regulation of adenosine receptors in the frontal cortex in Alzheimer's disease. Brain Pathol 2008; 18: 211-219. (Pubitemid 351430397)
29. Delarasse C, Auger R, Gonnord P, Fontaine B, Kanellopoulos JM. The purinergic receptor P2-7 triggers alpha-secretase-dependent processing of the amyloid precursor protein. J Biol Chem 2011; 286: 2596-2606.
30. Camden JM, Schrader AM, Camden RE, Gonzá lez FA, Erb L, Seye CI et al. P2Y2 nucleotide receptors enhance alpha-secretase-dependent amyloid precursor protein processing. J Biol Chem 2005; 280: 18696-18702. (Pubitemid 41379570)
31. Rivkin A, Ahearn SP, Chichetti SM, Hamblett CL, Garcia Y, Martinez M et al. Purine derivatives as potent gamma-secretase modulators. Bioorg Med Chem Lett 2010; 20: 2279-2282.
32. Arlt S, Schwedhelm E, Kolsch H, Jahn H, Linnebank M, Smulders Y et al. Dimethylarginines, homocysteine metabolism, and cerebrospinal fluid markers for Alzheimer's disease. J Alzheimers Dis 2012; 31: 751-758.
33. Smach MA, Jacob N, Golmard JL, Charfeddine B, Lammouchi T, Ben Othman L et al. Folate and homocysteine in the cerebrospinal fluid of patients with Alzheimer's disease or dementia: a case control study. Eur Neurol 2011; 65: 270-278.